JP2000506165A - 細胞インターナリゼーションを増強するための物質および方法 - Google Patents

細胞インターナリゼーションを増強するための物質および方法

Info

Publication number: JP2000506165A
Authority: JP; Japan
Prior art keywords: composition; apparent viscosity; cytosol; target cell; agent
Prior art date: 1996-03-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP9531869A

Other languages

English (en)

Japanese (ja)

Other versions

JP2000506165A5 (2

Inventor

エイ．エドワーズ，デイビッド

アール．ディーバー，ダニエル

エス．レインジャー，ロバート

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Massachusetts Institute of Technology

Original Assignee

Massachusetts Institute of Technology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-04

Filing date

1997-03-03

Publication date

2000-05-23

1997-03-03 Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology

2000-05-23 Publication of JP2000506165A publication Critical patent/JP2000506165A/ja

2005-02-10 Publication of JP2000506165A5 publication Critical patent/JP2000506165A5/ja

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 71
239000000463 material Substances 0.000 title description 5
230000002708 enhancing effect Effects 0.000 title description 4
210000004027 cell Anatomy 0.000 claims abstract description 88
239000000203 mixture Substances 0.000 claims abstract description 83
150000001875 compounds Chemical class 0.000 claims abstract description 44
210000000172 cytosol Anatomy 0.000 claims abstract description 28
229940079593 drug Drugs 0.000 claims abstract description 24
239000003814 drug Substances 0.000 claims abstract description 24
239000000017 hydrogel Substances 0.000 claims abstract description 21
108010001857 Cell Surface Receptors Proteins 0.000 claims abstract description 14
239000003446 ligand Substances 0.000 claims abstract description 14
229940039227 diagnostic agent Drugs 0.000 claims abstract description 6
239000000032 diagnostic agent Substances 0.000 claims abstract description 6
239000011345 viscous material Substances 0.000 claims abstract description 6
239000003795 chemical substances by application Substances 0.000 claims abstract 13
102000006240 membrane receptors Human genes 0.000 claims abstract 5
102000005962 receptors Human genes 0.000 claims description 27
108020003175 receptors Proteins 0.000 claims description 27
108090000623 proteins and genes Proteins 0.000 claims description 21
102000004169 proteins and genes Human genes 0.000 claims description 19
108090000765 processed proteins & peptides Proteins 0.000 claims description 14
230000003834 intracellular effect Effects 0.000 claims description 13
239000007788 liquid Substances 0.000 claims description 13
150000002632 lipids Chemical class 0.000 claims description 11
239000002502 liposome Substances 0.000 claims description 11
108020004414 DNA Proteins 0.000 claims description 9
239000008279 sol Substances 0.000 claims description 8
239000002246 antineoplastic agent Substances 0.000 claims description 7
150000004676 glycans Chemical class 0.000 claims description 7
229920001282 polysaccharide Polymers 0.000 claims description 7
239000005017 polysaccharide Substances 0.000 claims description 7
102000053642 Catalytic RNA Human genes 0.000 claims description 6
108090000994 Catalytic RNA Proteins 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
239000000969 carrier Substances 0.000 claims description 6
229940088597 hormone Drugs 0.000 claims description 6
239000005556 hormone Substances 0.000 claims description 6
102000039446 nucleic acids Human genes 0.000 claims description 6
108020004707 nucleic acids Proteins 0.000 claims description 6
150000007523 nucleic acids Chemical class 0.000 claims description 6
108091092562 ribozyme Proteins 0.000 claims description 6
108091034117 Oligonucleotide Proteins 0.000 claims description 5
239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
229920002678 cellulose Polymers 0.000 claims description 5
239000001913 cellulose Substances 0.000 claims description 5
229940127089 cytotoxic agent Drugs 0.000 claims description 5
-1 lipogel Substances 0.000 claims description 5
239000002773 nucleotide Substances 0.000 claims description 5
125000003729 nucleotide group Chemical group 0.000 claims description 5
229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
108010010803 Gelatin Proteins 0.000 claims description 4
108090001090 Lectins Proteins 0.000 claims description 4
102000004856 Lectins Human genes 0.000 claims description 4
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
229940072056 alginate Drugs 0.000 claims description 4
229920000615 alginic acid Polymers 0.000 claims description 4
235000010443 alginic acid Nutrition 0.000 claims description 4
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
229920000159 gelatin Polymers 0.000 claims description 4
239000008273 gelatin Substances 0.000 claims description 4
235000019322 gelatine Nutrition 0.000 claims description 4
235000011852 gelatine desserts Nutrition 0.000 claims description 4
229920002674 hyaluronan Polymers 0.000 claims description 4
229960003160 hyaluronic acid Drugs 0.000 claims description 4
239000002523 lectin Substances 0.000 claims description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
229920000936 Agarose Polymers 0.000 claims description 3
102000055006 Calcitonin Human genes 0.000 claims description 3
108060001064 Calcitonin Proteins 0.000 claims description 3
229920002307 Dextran Polymers 0.000 claims description 3
102000004190 Enzymes Human genes 0.000 claims description 3
108090000790 Enzymes Proteins 0.000 claims description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
241000700605 Viruses Species 0.000 claims description 3
108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 3
229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 3
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 3
229960004015 calcitonin Drugs 0.000 claims description 3
150000001720 carbohydrates Chemical class 0.000 claims description 3
229920001577 copolymer Polymers 0.000 claims description 3
239000000693 micelle Substances 0.000 claims description 3
239000011859 microparticle Substances 0.000 claims description 3
229920000233 poly(alkylene oxides) Polymers 0.000 claims description 3
108010088751 Albumins Proteins 0.000 claims description 2
102000009027 Albumins Human genes 0.000 claims description 2
239000000853 adhesive Substances 0.000 claims description 2
230000001070 adhesive effect Effects 0.000 claims description 2
229940050528 albumin Drugs 0.000 claims description 2
210000004369 blood Anatomy 0.000 claims description 2
239000008280 blood Substances 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
210000004072 lung Anatomy 0.000 claims description 2
102100022712 Alpha-1-antitrypsin Human genes 0.000 claims 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 4
102000016911 Deoxyribonucleases Human genes 0.000 claims 3
108010053770 Deoxyribonucleases Proteins 0.000 claims 3
108091023037 Aptamer Proteins 0.000 claims 2
239000000074 antisense oligonucleotide Substances 0.000 claims 2
238000012230 antisense oligonucleotides Methods 0.000 claims 2
239000002105 nanoparticle Substances 0.000 claims 2
229920002554 vinyl polymer Polymers 0.000 claims 2
108090000695 Cytokines Proteins 0.000 claims 1
102000004127 Cytokines Human genes 0.000 claims 1
239000003130 blood coagulation factor inhibitor Substances 0.000 claims 1
210000000170 cell membrane Anatomy 0.000 abstract description 17
210000001331 nose Anatomy 0.000 abstract description 4
210000001215 vagina Anatomy 0.000 abstract description 4
230000000975 bioactive effect Effects 0.000 abstract description 3
210000001508 eye Anatomy 0.000 abstract description 2
210000000214 mouth Anatomy 0.000 abstract description 2
230000002685 pulmonary effect Effects 0.000 abstract description 2
210000000664 rectum Anatomy 0.000 abstract description 2
230000000241 respiratory effect Effects 0.000 abstract description 2
239000012867 bioactive agent Substances 0.000 abstract 1
239000012528 membrane Substances 0.000 description 56
210000004379 membrane Anatomy 0.000 description 54
229920003091 Methocel™ Polymers 0.000 description 29
239000000243 solution Substances 0.000 description 28
230000012202 endocytosis Effects 0.000 description 19
230000001965 increasing effect Effects 0.000 description 19
230000010837 receptor-mediated endocytosis Effects 0.000 description 19
238000009739 binding Methods 0.000 description 16
230000027455 binding Effects 0.000 description 15
108010000817 Leuprolide Proteins 0.000 description 13
241001494479 Pecora Species 0.000 description 13
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 13
229960004338 leuprorelin Drugs 0.000 description 13
229920000642 polymer Polymers 0.000 description 13
210000003722 extracellular fluid Anatomy 0.000 description 12
229920000609 methyl cellulose Polymers 0.000 description 11
239000001923 methylcellulose Substances 0.000 description 11
235000010981 methylcellulose Nutrition 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
239000000126 substance Substances 0.000 description 10
102000000844 Cell Surface Receptors Human genes 0.000 description 9
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 9
108010004977 Vasopressins Proteins 0.000 description 9
102000002852 Vasopressins Human genes 0.000 description 9
230000001413 cellular effect Effects 0.000 description 9
229960003726 vasopressin Drugs 0.000 description 9
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 8
230000001086 cytosolic effect Effects 0.000 description 8
239000012530 fluid Substances 0.000 description 8
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
230000007423 decrease Effects 0.000 description 7
239000000499 gel Substances 0.000 description 7
239000000872 buffer Substances 0.000 description 6
150000001768 cations Chemical class 0.000 description 6
210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000033001 locomotion Effects 0.000 description 6
230000008884 pinocytosis Effects 0.000 description 6
230000009885 systemic effect Effects 0.000 description 6
230000002378 acidificating effect Effects 0.000 description 5
210000000805 cytoplasm Anatomy 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
229960000890 hydrocortisone Drugs 0.000 description 5
230000008569 process Effects 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
230000032258 transport Effects 0.000 description 5
102000005853 Clathrin Human genes 0.000 description 4
108010019874 Clathrin Proteins 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
102000004338 Transferrin Human genes 0.000 description 4
108090000901 Transferrin Proteins 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
229930193282 clathrin Natural products 0.000 description 4
210000003527 eukaryotic cell Anatomy 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000008188 pellet Substances 0.000 description 4
229920001983 poloxamer Polymers 0.000 description 4
229920002627 poly(phosphazenes) Polymers 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000012581 transferrin Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
239000012981 Hank's balanced salt solution Substances 0.000 description 3
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 3
101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 3
102100024028 Progonadoliberin-1 Human genes 0.000 description 3
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 3
102000007238 Transferrin Receptors Human genes 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
229920001400 block copolymer Polymers 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 3
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 3
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
125000001841 imino group Chemical group [H]N=* 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
229920002521 macromolecule Polymers 0.000 description 3
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
238000002604 ultrasonography Methods 0.000 description 3
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
208000034423 Delivery Diseases 0.000 description 2
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
208000036566 Erythroleukaemia Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
101710159527 Maturation protein A Proteins 0.000 description 2
101710091157 Maturation protein A2 Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108010025020 Nerve Growth Factor Proteins 0.000 description 2
102000015336 Nerve Growth Factor Human genes 0.000 description 2
102000003982 Parathyroid hormone Human genes 0.000 description 2
108090000445 Parathyroid hormone Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
208000021841 acute erythroid leukemia Diseases 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
229910001424 calcium ion Inorganic materials 0.000 description 2
125000002843 carboxylic acid group Chemical group 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
210000002314 coated vesicle Anatomy 0.000 description 2
238000002591 computed tomography Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002612 dispersion medium Substances 0.000 description 2
230000005684 electric field Effects 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000002595 magnetic resonance imaging Methods 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
239000000199 parathyroid hormone Substances 0.000 description 2
229960001319 parathyroid hormone Drugs 0.000 description 2
239000002245 particle Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
239000002994 raw material Substances 0.000 description 2
239000003488 releasing hormone Substances 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
230000004044 response Effects 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
125000000542 sulfonic acid group Chemical group 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
229920001059 synthetic polymer Polymers 0.000 description 2
238000012360 testing method Methods 0.000 description 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
230000009677 vaginal delivery Effects 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
102000007625 Hirudins Human genes 0.000 description 1
108010007267 Hirudins Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102100020873 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000008238 LHRH Receptors Human genes 0.000 description 1
108010021290 LHRH Receptors Proteins 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
102000003729 Neprilysin Human genes 0.000 description 1
108090000028 Neprilysin Proteins 0.000 description 1
102400000050 Oxytocin Human genes 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
102000013275 Somatomedins Human genes 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
108010033576 Transferrin Receptors Proteins 0.000 description 1
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
108091005764 adaptor proteins Proteins 0.000 description 1
102000035181 adaptor proteins Human genes 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108010054176 apotransferrin Proteins 0.000 description 1
238000013459 approach Methods 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229940105657 catalase Drugs 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
210000002806 clathrin-coated vesicle Anatomy 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
229920006237 degradable polymer Polymers 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
108700025485 deslorelin Proteins 0.000 description 1
229960004165 deslorelin acetate Drugs 0.000 description 1
OFQNFLLLCMQNEP-MIPXGPCFSA-N deterelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OFQNFLLLCMQNEP-MIPXGPCFSA-N 0.000 description 1
108700027435 detirelix Proteins 0.000 description 1
229950003747 detirelix Drugs 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
238000002594 fluoroscopy Methods 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
230000008217 follicular development Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
229940006607 hirudin Drugs 0.000 description 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000005398 intermolecular potential Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000002977 intracellular fluid Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000009545 invasion Effects 0.000 description 1
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
229960003451 lactitol Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002717 polyvinylpyridine Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000004064 recycling Methods 0.000 description 1
108010026906 renin inhibitory peptide Proteins 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229960004025 sodium salicylate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
239000013598 vector Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Otolaryngology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP9531869A 1996-03-04 1997-03-03 細胞インターナリゼーションを増強するための物質および方法 Pending JP2000506165A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1272196P	1996-03-04	1996-03-04
US60/012,721		1996-03-04
PCT/US1997/003276 WO1997032572A2 (en)	1996-03-04	1997-03-03	Materials and methods for enhancing cellular internalization

Publications (2)

Publication Number	Publication Date
JP2000506165A true JP2000506165A (ja)	2000-05-23
JP2000506165A5 JP2000506165A5 (2)	2005-02-10

Family

ID=21756381

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP9531869A Pending JP2000506165A (ja)	1996-03-04	1997-03-03	細胞インターナリゼーションを増強するための物質および方法

Country Status (9)

Country	Link
US (1)	US5985320A (2)
EP (1)	EP0885002B1 (2)
JP (1)	JP2000506165A (2)
AT (1)	ATE508733T1 (2)
AU (1)	AU2063197A (2)
DK (1)	DK0885002T3 (2)
ES (1)	ES2395214T3 (2)
PT (1)	PT885002E (2)
WO (1)	WO1997032572A2 (2)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003534366A (ja) *	2000-05-25	2003-11-18	アルカームズコントロールドセラピューティクスインコーポレイテッド	改善された注射性を有する注射可能な懸濁物の調製
JPWO2004078213A1 (ja) *	2003-03-06	2006-06-08	千佳子錦織	対象物質導入用組成物及び対象物質導入方法
JP2007525463A (ja) *	2003-05-12	2007-09-06	ベクトン・ディキンソン・アンド・カンパニー	インフルエンザワクチンの真皮送達を向上する分子
JP2007529558A (ja) *	2004-03-19	2007-10-25	レット・ゼア・ビー・ホープ、メディカル、リサーチ、インスティテュート	Ｃｔｌ／ｃｔｌｄの細胞炭水化物認識ドメインへターゲティングするための炭水化物誘導体化リポソーム、および治療的に活性な化合物の細胞内送達

Families Citing this family (301)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0920339A2 (en) *	1996-07-09	1999-06-09	The Johns Hopkins University	Gene delivery system
IT1289608B1 (it) *	1997-02-05	1998-10-15	Angelini Ricerche Spa	Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale
US6593369B2 (en)	1997-10-20	2003-07-15	Vivus, Inc.	Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US7087236B1 (en)	1998-09-01	2006-08-08	Merrion Research I Limited	Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
AU759016B2 (en)	1998-10-05	2003-04-03	Penn State Research Foundation, The	Compositions and methods for enhancing receptor-mediated cellular internalization
US20050153926A1 (en) *	1998-12-04	2005-07-14	Adams Christopher P.	Method for the immobilization of oligonucleotides
US7273618B2 (en) *	1998-12-09	2007-09-25	Chiron Corporation	Method for administering agents to the central nervous system
US8114850B2 (en)	1999-04-08	2012-02-14	Advanced Cancer Therapeutics, Llc	Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en)	1999-04-08	2011-06-14	Advanced Cancer Therapeutics, Llc	Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
EP1181304B1 (en)	1999-04-08	2007-10-10	Antisoma Research Limited	Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
CA2398466A1 (en)	2000-01-27	2001-08-02	Medimmune, Inc.	Ultra high affinity neutralizing antibodies
US7229619B1 (en)	2000-11-28	2007-06-12	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6262020B1 (en) *	2000-02-15	2001-07-17	Alphamed Pharmaceuticals Corp.	Topical wound therapeutic compositions
EP2341075A1 (en) *	2000-03-01	2011-07-06	MedImmune, LLC	Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
CA2401239A1 (en) *	2000-03-03	2001-09-13	Valentis, Inc.	Improved poloxamer and poloxamine compositions for nucleic acid delivery
US20040009940A1 (en) *	2000-10-20	2004-01-15	Coleman Michael E.	Gene delivery formulations and methods for treatment of ischemic conditions
EP2412384A1 (en)	2000-11-28	2012-02-01	MedImmune, LLC	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) *	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en)	2000-11-28	2004-11-16	Medimmune, Inc.	Anti-RSV antibodies
US7179900B2 (en)	2000-11-28	2007-02-20	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PT1355919E (pt)	2000-12-12	2011-03-02	Medimmune Llc	Moléculas com semivida longa, composições que as contêm e suas utilizações
ES2390425T3 (es)	2000-12-22	2012-11-12	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
US6848197B2 (en) *	2001-04-18	2005-02-01	Advanced Inhalation Research, Inc.	Control of process humidity to produce large, porous particles
US20030134810A1 (en) *	2001-10-09	2003-07-17	Chris Springate	Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
WO2003046144A2 (en) *	2001-11-26	2003-06-05	Molecular Reflections, Inc.	Microscale immobilization of molecules using a hydrogel and methods of use thereof
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
WO2004010935A2 (en) *	2002-07-25	2004-02-05	Medimmune, Inc.	Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
EP1534335B9 (en)	2002-08-14	2016-01-13	Macrogenics, Inc.	Fcgammariib-specific antibodies and methods of use thereof
SI2301965T1 (sl)	2002-10-16	2015-07-31	Purdue Pharma L.P.	Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
US7483738B2 (en) *	2002-11-29	2009-01-27	Power Paper Ltd.	Combination stimulating and exothermic heating device and method of use thereof
JP2006524039A (ja)	2003-01-09	2006-10-26	マクロジェニクス，インコーポレーテッド	変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2004062619A2 (en)	2003-01-13	2004-07-29	Macrogenics, Inc.	SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP4764818B2 (ja)	2003-04-11	2011-09-07	メディミューン，エルエルシー	組換えｉｌ−９抗体およびその使用
CA2528064C (en) *	2003-06-13	2010-01-12	Advanced Inhalation Research, Inc.	Low dose pharmaceutical powders for inhalation
EP1660186B1 (en)	2003-08-18	2013-12-25	MedImmune, LLC	Humanization of antibodies
PT1684782E (pt)	2003-10-03	2015-12-21	Thorn Bioscience Llc	Processo para a sincronização da ovulação para reprodução regulada sem detecção do cio
CA2574977C (en) *	2004-07-29	2010-01-26	X-Sten, Corp.	Spinal ligament modification devices
WO2006018899A1 (ja) *	2004-08-17	2006-02-23	Bml, Inc.	検出用器具を用いた検出方法
WO2006034292A2 (en)	2004-09-21	2006-03-30	Medimmune, Inc.	Antibodies against and methods for producing vaccines for respiratory syncytial virus
AU2005302453A1 (en) *	2004-10-29	2006-05-11	Medimmune, Llc	Methods of preventing and treating RSV infections and related conditions
JP5153613B2 (ja)	2005-03-18	2013-02-27	メディミューン，エルエルシー	抗体のフレームワーク・シャッフル
EP3479844B1 (en)	2005-04-15	2023-11-22	MacroGenics, Inc.	Covalent diabodies and uses thereof
EP1893647A2 (en)	2005-06-23	2008-03-05	MedImmune, Inc.	Antibody formulations having optimized aggregation and fragmentation profiles
US20070003528A1 (en) *	2005-06-29	2007-01-04	Paul Consigny	Intracoronary device and method of use thereof
CN103145839A (zh) *	2005-06-30	2013-06-12	Abbvie公司	Il-12/p40结合蛋白
JP2009502365A (ja)	2005-07-29	2009-01-29	ヴァートスメディカルインコーポレーテッド	経皮的組織切除装置および同方法
HUE029465T2 (en)	2005-08-10	2017-02-28	Macrogenics Inc	Identification and engineering of antibodies with variant Fc regions and methods of using same
KR20130108481A (ko)	2005-08-19	2013-10-02	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
EP2500356A3 (en)	2005-08-19	2012-10-24	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
CN101277974A (zh)	2005-09-30	2008-10-01	阿伯特有限及两合公司	排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
RU2432362C2 (ru)	2005-11-30	2011-10-27	Эбботт Лэборетриз	Моноклональные антитела и их применения
PL2289909T3 (pl)	2005-11-30	2015-04-30	Abbvie Inc	Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
US7942830B2 (en)	2006-05-09	2011-05-17	Vertos Medical, Inc.	Ipsilateral approach to minimally invasive ligament decompression procedure
HUE030269T2 (en)	2006-06-26	2017-04-28	Macrogenics Inc	FC RIIB-specific antibodies and methods for their use
ES2439994T3 (es)	2006-08-28	2014-01-27	Kyowa Hakko Kirin Co., Ltd.	Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
CA2914170C (en)	2006-09-08	2018-10-30	Abbvie Bahamas Ltd.	Interleukin-13 binding proteins
AU2007313300A1 (en)	2006-10-16	2008-04-24	Medimmune, Llc.	Molecules with reduced half-lives, compositions and uses thereof
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
AU2007234612B2 (en)	2006-12-14	2013-06-27	Johnson & Johnson Regenerative Therapeutics, Llc	Protein stabilization formulations
EP2124952A2 (en)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Method for the treatment of amyloidoses
AU2008246442B2 (en)	2007-05-04	2014-07-03	Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa	Engineered rabbit antibody variable domains and uses thereof
US20090232801A1 (en) *	2007-05-30	2009-09-17	Abbot Laboratories	Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
PE20090329A1 (es) *	2007-05-30	2009-03-27	Abbott Lab	Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
EP3424951A1 (en)	2007-06-21	2019-01-09	MacroGenics, Inc.	Covalent diabodies and uses thereof
US7678764B2 (en)	2007-06-29	2010-03-16	Johnson & Johnson Regenerative Therapeutics, Llc	Protein formulations for use at elevated temperatures
KR20100058509A (ko)	2007-07-31	2010-06-03	메디뮨 엘엘씨	다중특이적 에피토프 결합 단백질 및 이의 용도
CN101801405A (zh)	2007-08-07	2010-08-11	先进科技及再生医学有限责任公司	包含于酸性水溶液中的gdf-5的蛋白质配方
JP2011509675A (ja)	2008-01-18	2011-03-31	メディミューン，エルエルシー	部位特異的コンジュゲーションのためのシステイン操作抗体
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
BRPI0911048A2 (pt) *	2008-04-14	2015-12-29	Atrm Llc	formulações líquidas tamponadas de gdf-5
BRPI0910482A2 (pt)	2008-04-29	2019-09-24	Abbott Lab	imunoglobinas de domínio variável duplo e usos das mesmas
MX2010012142A (es)	2008-05-09	2011-04-05	Abbott Gmbh & Co Kg	Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
BRPI0913366A8 (pt)	2008-06-03	2017-07-11	Abbott Lab	Imunoglobulinas de domínio variável duplo e seus usos
PE20100092A1 (es)	2008-06-03	2010-03-12	Abbott Lab	Inmunoglobulina con dominio variable dual y usos de la misma
WO2010006059A1 (en)	2008-07-08	2010-01-14	Abbott Laboratories	Prostaglandin e2 binding proteins and uses thereof
NZ603698A (en)	2008-07-08	2014-03-28	Abbvie Inc	Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
USD619252S1 (en)	2008-10-23	2010-07-06	Vertos Medical, Inc.	Tissue modification device
USD611146S1 (en)	2008-10-23	2010-03-02	Vertos Medical, Inc.	Tissue modification device
USD619253S1 (en)	2008-10-23	2010-07-06	Vertos Medical, Inc.	Tissue modification device
USD621939S1 (en)	2008-10-23	2010-08-17	Vertos Medical, Inc.	Tissue modification device
USD610259S1 (en)	2008-10-23	2010-02-16	Vertos Medical, Inc.	Tissue modification device
MX2011005953A (es) *	2008-12-04	2011-08-17	Abbott Lab	Inmunoglobulinas de dominio variable dual y usos de las mismas.
EP2376109B1 (en)	2008-12-19	2019-01-23	MacroGenics, Inc.	Covalent diabodies and uses thereof
US20110165063A1 (en) *	2009-01-29	2011-07-07	Abbott Laboratories	Il-1 binding proteins
SG172855A1 (en) *	2009-01-29	2011-08-29	Abbott Lab	Il-1 binding proteins
US8852608B2 (en)	2009-02-02	2014-10-07	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8030026B2 (en)	2009-02-24	2011-10-04	Abbott Laboratories	Antibodies to troponin I and methods of use thereof
EP2403531A4 (en)	2009-03-05	2013-02-27	Abbott Lab	IL-17 BINDING PROTEINS
US8283162B2 (en) *	2009-03-10	2012-10-09	Abbott Laboratories	Antibodies relating to PIVKAII and uses thereof
RU2568839C2 (ru)	2009-04-23	2015-11-20	ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК	Способ и композиция для синхронизации времени осеменения
WO2010141329A1 (en)	2009-06-01	2010-12-09	Medimmune, Llc	Molecules with extended half-lives and uses thereof
AU2010270979B2 (en)	2009-06-22	2015-04-23	Medimmune, Llc	Engineered Fc regions for site-specific conjugation
PL2464664T3 (pl)	2009-08-13	2016-02-29	Crucell Holland Bv	Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania
WO2011025964A2 (en)	2009-08-29	2011-03-03	Abbott Laboratories	Therapeutic dll4 binding proteins
KR20120060877A (ko)	2009-09-01	2012-06-12	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
WO2011035205A2 (en)	2009-09-18	2011-03-24	Calmune Corporation	Antibodies against candida, collections thereof and methods of use
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
WO2011044368A1 (en)	2009-10-07	2011-04-14	Macrogenics, Inc.	Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
AU2010306677B2 (en)	2009-10-15	2013-05-23	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
US8420083B2 (en)	2009-10-31	2013-04-16	Abbvie Inc.	Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
CN102656190A (zh)	2009-12-08	2012-09-05	雅培股份有限两合公司	用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
BR112012021941A2 (pt)	2010-03-02	2022-02-01	Abbvie Inc	Proteínas terapêuticas de ligação a dll4
PE20130203A1 (es)	2010-03-17	2013-03-24	Abbott Res Bv	Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
ES2684475T3 (es)	2010-04-15	2018-10-03	Abbvie Inc.	Proteínas que se unen a beta amiloide
EP4234698A3 (en)	2010-05-06	2023-11-08	Novartis AG	Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
KR20130066631A (ko)	2010-05-06	2013-06-20	노파르티스 아게	치료적 저밀도 지단백질-관련 단백질 ６（ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
KR101539684B1 (ko)	2010-05-14	2015-07-27	애브비 인코포레이티드	Ｉｌ－１ 결합 단백질
EP2585094B1 (en)	2010-06-25	2018-08-01	INSERM - Institut National de la Santé et de la Recherche Médicale	Flagellin polypeptide as tlr5 agonist for use in the treatment of respiratory tract infections
US20120009196A1 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
PH12012502244A1 (en)	2010-07-09	2016-09-30	Crucell Holland Bv	Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
US9120862B2 (en)	2010-07-26	2015-09-01	Abbott Laboratories	Antibodies relating to PIVKA-II and uses thereof
EP2601216B1 (en)	2010-08-02	2018-01-03	MacroGenics, Inc.	Covalent diabodies and uses thereof
US8735546B2 (en)	2010-08-03	2014-05-27	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
CN103298833B (zh)	2010-08-14	2015-12-16	Abbvie公司	β淀粉样蛋白结合蛋白
US9505829B2 (en)	2010-08-19	2016-11-29	Zoetis Belgium S.A.	Anti-NGF antibodies and their use
GB201013989D0 (en)	2010-08-20	2010-10-06	Univ Southampton	Biological materials and methods of using the same
NZ607337A (en)	2010-08-20	2015-06-26	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
PE20140229A1 (es)	2010-08-26	2014-03-27	Abbvie Inc	Inmunoglobulinas con dominio variable dual y usos de las mismas
US20130245233A1 (en)	2010-11-24	2013-09-19	Ming Lei	Multispecific Molecules
WO2012088094A2 (en)	2010-12-21	2012-06-28	Abbott Laboratories	Il-1 binding proteins
CN103517921B (zh)	2010-12-21	2017-07-18	Abbvie 公司	IL‑1‑α和‑β双特异性双重可变结构域免疫球蛋白及其用途
KR101970025B1 (ko)	2011-04-20	2019-04-17	메디뮨 엘엘씨	Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
CA2836873C (en)	2011-05-21	2019-10-22	Macrogenics, Inc.	Deimmunized serum-binding domains and their use for extending serum half-life
EP2734236A4 (en)	2011-07-13	2015-04-15	Abbvie Inc	METHOD AND COMPOSITIONS FOR TREATING ASTHMA WITH ANTI-IL-13 ANTIBODIES
US9238689B2 (en)	2011-07-15	2016-01-19	Morpho Sys AG	Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
JP6120848B2 (ja)	2011-08-15	2017-04-26	メディミューン，エルエルシー	抗ｂ７−ｈ４抗体およびその使用
JP2014533659A (ja)	2011-10-24	2014-12-15	アッヴィ・インコーポレイテッド	スクレロスチンに対するイムノバインダー
SG10201604104PA (en)	2011-10-25	2016-07-28	Prothena Therapeutics Ltd	Antibody formulations and methods
KR20140103135A (ko)	2011-12-05	2014-08-25	노파르티스 아게	Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
AU2012349735B2 (en)	2011-12-05	2016-05-19	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (HER3)
CN104144947B (zh)	2011-12-14	2017-10-27	艾伯维德国有限责任两合公司	用于诊断和治疗铁相关病症的组合物和方法
EP2791175A2 (en)	2011-12-14	2014-10-22	Abbvie Deutschland GmbH & Co. KG	Composition and method for the diagnosis and treatment of iron-related disorders
JP2015502397A (ja)	2011-12-23	2015-01-22	ファイザー・インク	部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
AR089529A1 (es)	2011-12-30	2014-08-27	Abbvie Inc	Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
NZ714482A (en)	2012-01-27	2017-08-25	Abbvie Inc	Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
EP2855520B1 (en)	2012-06-04	2018-09-26	Novartis AG	Site-specific labeling methods and molecules produced thereby
EP2859018B1 (en)	2012-06-06	2021-09-22	Zoetis Services LLC	Caninized anti-ngf antibodies and methods thereof
UY34905A (es)	2012-07-12	2014-01-31	Abbvie Inc	Proteínas de unión a il-1
KR20180008921A (ko)	2012-11-01	2018-01-24	애브비 인코포레이티드	항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
HK1216428A1 (zh)	2012-11-09	2016-11-11	辉瑞公司	血小板衍生生长因子b之特异性抗体及其组合物和用途
DK2925339T3 (da)	2012-11-28	2020-07-20	United Ah Ii Llc	Fremgangsmåde til synkronisering af inseminationstidspunkt hos gylte
AU2013361275B2 (en)	2012-12-19	2016-11-24	Amplimmune, Inc.	Anti-human B7-H4 antibodies and their uses
MX2015008117A (es)	2012-12-21	2016-03-31	Amplimmune Inc	Anticuerpos anti-h7cr.
WO2014124258A2 (en)	2013-02-08	2014-08-14	Irm Llc	Specific sites for modifying antibodies to make immunoconjugates
KR102447350B1 (ko)	2013-02-08	2022-09-23	노파르티스 아게	면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
US9498532B2 (en)	2013-03-13	2016-11-22	Novartis Ag	Antibody drug conjugates
BR112015023239A8 (pt)	2013-03-14	2018-04-17	Abbott Lab	ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
EP2970479B1 (en)	2013-03-14	2019-04-24	Novartis AG	Antibodies against notch 3
JP2016512241A (ja)	2013-03-14	2016-04-25	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
CN113549148B (zh)	2013-03-14	2025-11-21	雅培制药有限公司	Hcv核心脂质结合结构域单克隆抗体
US9469686B2 (en)	2013-03-15	2016-10-18	Abbott Laboratories	Anti-GP73 monoclonal antibodies and methods of obtaining the same
NZ710929A (en)	2013-03-15	2018-02-23	Novartis Ag	Antibody drug conjugates
CN105324396A (zh)	2013-03-15	2016-02-10	艾伯维公司	针对IL-1β和/或IL-17的双重特异性结合蛋白
BR112015029395A2 (pt)	2013-05-24	2017-09-19	Medimmune Llc	Anticorpos anti-b7-h5 e seus usos
WO2014194293A1 (en)	2013-05-30	2014-12-04	Amplimmune, Inc.	Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
SG11201509982UA (2)	2013-06-06	2016-04-28	Igenica Biotherapeutics Inc
US10183988B2 (en)	2013-06-07	2019-01-22	Duke University	Anti-Complement factor H antibodies
UA116479C2 (uk)	2013-08-09	2018-03-26	Макродженікс, Інк.	БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en)	2013-08-09	2022-07-12	Macrogenics, Inc.	Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2839842A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
KR20160055275A (ko)	2013-09-17	2016-05-17	유니버시티 헬스 네트워크	시스 ｒｇｍａ/네오제닌 상호작용 또는 지질 래프트에 대해 지시되는 제제 및 치료 방법에서의 이의 용도
US10287572B2 (en)	2013-11-01	2019-05-14	Regents Of The University Of Minnesota	Protein scaffolds and methods of use
MX388027B (es)	2013-11-13	2025-03-19	Pfizer	Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
WO2015084883A2 (en)	2013-12-02	2015-06-11	Abbvie, Inc.	Compositions and methods for treating osteoarthritis
WO2015109212A1 (en)	2014-01-17	2015-07-23	Pfizer Inc.	Anti-il-2 antibodies and compositions and uses thereof
WO2015110930A1 (en)	2014-01-24	2015-07-30	Pfizer Inc.	Modified interleukin 21 receptor proteins
KR20160135190A (ko)	2014-02-14	2016-11-25	앤드류 에스. 카이	혈관형성 암의 치료를 위한 개선된 방법
US10272117B2 (en)	2014-02-24	2019-04-30	Celgene Corporation	Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
WO2015138337A1 (en)	2014-03-09	2015-09-17	Abbvie, Inc.	Compositions and methods for treating rheumatoid arthritis
CA2940451A1 (en)	2014-03-12	2015-09-17	Novartis Ag	Specific sites for modifying antibodies to make immunoconjugates
TWI731535B (zh)	2014-03-21	2021-06-21	美商艾伯維有限公司	抗-egfr抗體及抗體藥物結合物
EP3142700B1 (en)	2014-05-16	2021-03-03	Medimmune, LLC	Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
EP3152235B1 (en)	2014-05-29	2021-08-25	MacroGenics, Inc.	Tri-specific binding molecules and methods of use thereof
CA2951532A1 (en) *	2014-06-16	2015-12-23	Zoetis Services Llc	Intravaginal formulations comprising gnrh
TWI693232B (zh)	2014-06-26	2020-05-11	美商宏觀基因股份有限公司	與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
WO2016011167A1 (en)	2014-07-16	2016-01-21	Dana-Farber Cancer Institute, Inc., Et Al	Her3 inhibition in low-grade serous ovarian cancers
US10786578B2 (en)	2014-08-05	2020-09-29	Novartis Ag	CKIT antibody drug conjugates
KR20170040249A (ko)	2014-08-12	2017-04-12	노파르티스 아게	항-cdh6 항체 약물 접합체
EA201790719A1 (ru)	2014-09-26	2017-07-31	Макродженикс, Инк.	Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
AU2015360502A1 (en)	2014-12-10	2017-06-29	Regents Of The University Of Minnesota	Genetically modified cells, tissues, and organs for treating disease
PL3333191T3 (pl)	2014-12-11	2021-05-04	Pierre Fabre Médicament	Przeciwciała przeciwko c10orf54 i ich zastosowania
WO2016094881A2 (en)	2014-12-11	2016-06-16	Abbvie Inc.	Lrp-8 binding proteins
US10689459B2 (en)	2014-12-12	2020-06-23	Novartis Ag	Treatment of breast cancer brain metastases
US20160244520A1 (en)	2015-01-24	2016-08-25	Abbvie Inc.	Compositions and methods for treating psoriatic arthritis
SG11201706024YA (en)	2015-01-26	2017-08-30	Macrogenics Inc	Multivalent molecules comprising dr5-binding domains
WO2016120828A1 (en)	2015-01-30	2016-08-04	Novartis Ag	Treatment of breast cancer by m-csf antagonist
MX2017011194A (es)	2015-03-03	2018-04-10	Kymab Ltd	Anticuerpos, usos y métodos.
US10174121B2 (en)	2015-05-29	2019-01-08	Abbvie, Inc.	Anti-CD40 antibodies
TWI773646B (zh)	2015-06-08	2022-08-11	美商宏觀基因股份有限公司	結合lag-3的分子和其使用方法
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3310813A1 (en)	2015-06-17	2018-04-25	Novartis AG	Antibody drug conjugates
WO2017015619A1 (en)	2015-07-23	2017-01-26	The Regents Of The University Of California	Antibodies to coagulation factor xia and uses thereof
WO2017019846A1 (en)	2015-07-30	2017-02-02	Macrogenics, Inc.	Pd-1-binding molecules and methods use thereof
WO2017044862A1 (en)	2015-09-11	2017-03-16	Abbvie Inc.	Methods for treating relapsing forms of multiple sclerosis
US9862760B2 (en)	2015-09-16	2018-01-09	Novartis Ag	Polyomavirus neutralizing antibodies
CN108136010A (zh)	2015-10-08	2018-06-08	宏观基因有限公司	用于治疗癌症的联合疗法
US11849741B2 (en)	2015-10-20	2023-12-26	Savage River, Inc.	Meat-like food products
KR102876923B1 (ko)	2015-10-23	2025-10-28	화이자 인코포레이티드	항-il-2 항체 및 조성물 및 이의 용도
TN2018000112A1 (en)	2015-10-29	2019-10-04	Novartis Ag	Antibody conjugates comprising toll-like receptor agonist
KR102815803B1 (ko)	2015-12-02	2025-06-05	주식회사 에스티사이언스	당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
CN114470194A (zh)	2015-12-02	2022-05-13	斯特库伯株式会社	与btn1a1免疫特异性结合的抗体和分子及其治疗用途
US10954301B2 (en)	2015-12-14	2021-03-23	Macrogenics, Inc.	Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
WO2017125897A1 (en)	2016-01-21	2017-07-27	Novartis Ag	Multispecific molecules targeting cll-1
TW201730212A (zh)	2016-02-17	2017-09-01	宏觀基因股份有限公司	Ｒｏｒ１－結合分子及其使用方法
EP3423105B1 (en)	2016-03-02	2021-05-05	Eisai R&D Management Co., Ltd.	Eribulin-based antibody-drug conjugates and methods of use
TWI781098B (zh)	2016-04-15	2022-10-21	美商宏觀基因股份有限公司	新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
CN109496218A (zh)	2016-06-01	2019-03-19	艾伯维公司	用于治疗脊髓损伤和疼痛的抗反义导向分子a（rgma）拮抗性抗体
BR112018075630A2 (pt)	2016-06-08	2019-03-19	Abbvie Inc.	anticorpos anti-cd98 e conjugados de fármaco de anticorpo
EP3458479B1 (en)	2016-06-08	2020-11-04	AbbVie Inc.	Anti-b7-h3 antibodies and antibody drug conjugates
JP2019526529A (ja)	2016-06-08	2019-09-19	アッヴィ・インコーポレイテッド	抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
KR102379464B1 (ko)	2016-06-20	2022-03-29	키맵 리미티드	항-pd-l1 항체
EP3487521A4 (en)	2016-07-21	2020-07-01	Emory University	ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM
WO2018049078A1 (en)	2016-09-07	2018-03-15	Vertos Medical, Inc.	Percutaneous lateral recess resection methods and instruments
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018098370A1 (en)	2016-11-23	2018-05-31	Immunoah Therapeutics, Inc.	4-1bb binding proteins and uses thereof
JP2020513418A (ja)	2016-12-13	2020-05-14	エモリーユニバーシティ	ウイルス感染を管理するためのポリペプチド
EP3554544A4 (en)	2016-12-16	2020-07-29	Bluefin Biomedicine, Inc.	ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
CA3045592A1 (en)	2016-12-21	2018-06-28	Novartis Ag	Antibody drug conjugates for ablating hematopoietic stem cells
AR110424A1 (es)	2016-12-23	2019-03-27	Macrogenics Inc	Moléculas de unión a adam9 y métodos de uso de las mismas
EP3574017A1 (en)	2017-01-27	2019-12-04	Kymab Limited	Anti-opg antibodies
JOP20190187A1 (ar)	2017-02-03	2019-08-01	Novartis Ag	مترافقات عقار جسم مضاد لـ ccr7
WO2018185618A1 (en)	2017-04-03	2018-10-11	Novartis Ag	Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018195302A1 (en)	2017-04-19	2018-10-25	Bluefin Biomedicine, Inc.	Anti-vtcn1 antibodies and antibody drug conjugates
AR111651A1 (es)	2017-04-28	2019-08-07	Novartis Ag	Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US10865238B1 (en)	2017-05-05	2020-12-15	Duke University	Complement factor H antibodies
US12215151B2 (en)	2017-05-31	2025-02-04	Stcube & Co., Inc.	Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
KR20200015602A (ko)	2017-05-31	2020-02-12	주식회사 에스티큐브앤컴퍼니	Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
CN110997724A (zh)	2017-06-06	2020-04-10	斯特库伯株式会社	使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
CA3066918A1 (en)	2017-06-12	2018-12-20	Bluefin Biomedicine, Inc.	Anti-il1rap antibodies and antibody drug conjugates
JP7685835B2 (ja)	2017-12-01	2025-05-30	ノバルティスアーゲー	ポリオーマウイルス中和抗体
MX2020005662A (es)	2017-12-01	2020-08-20	Pfizer	Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
CA3090322A1 (en)	2018-02-12	2019-08-15	Diabetes-Free, Inc.	Improved antagonistic anti-human cd40 monoclonal antibodies
JP2021517461A (ja)	2018-03-12	2021-07-26	ゾエティス・サービシーズ・エルエルシー	抗ｎｇｆ抗体およびその方法
CA3094756A1 (en)	2018-03-29	2019-10-03	Pfizer Inc.	Lfa3 variants and compositions and uses thereof
US10654944B2 (en)	2018-04-10	2020-05-19	Y-Biologics Inc.	Cell engaging binding molecules
US11932681B2 (en)	2018-05-31	2024-03-19	Novartis Ag	Hepatitis B antibodies
JOP20200268A1 (ar)	2018-06-01	2020-10-26	Eisai R&D Man Co Ltd	تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
UY38251A (es)	2018-06-01	2019-12-31	Novartis Ag	Moléculas de unión contra bcma y usos de las mismas
TW202014209A (zh)	2018-06-20	2020-04-16	瑞士商諾華公司	用於消融造血幹細胞之抗體藥物軛合物
EP3826659B1 (en)	2018-07-10	2024-06-19	Rush University Medical Center	Immunomodulator for use in the treatment of a bacterial infection
KR102767692B1 (ko)	2018-07-20	2025-02-17	피에르 파브르 메디카먼트	Vista의 수용체
US11359024B2 (en)	2018-09-07	2022-06-14	Pfizer Inc.	Anti-AVB8 antibodies and compositions and uses thereof
WO2020053742A2 (en)	2018-09-10	2020-03-19	Novartis Ag	Anti-hla-hbv peptide antibodies
WO2020069498A1 (en)	2018-09-28	2020-04-02	Jochen Reiser	Supar and prediction and treatment of acute kidney injury
WO2020102454A1 (en)	2018-11-13	2020-05-22	Regents Of The University Of Minnesota	Cd40 targeted peptides and uses thereof
WO2020106358A1 (en)	2018-11-20	2020-05-28	Takeda Vaccines, Inc.	Novel anti-zika virus antibodies and uses thereof
PE20211473A1 (es)	2018-12-13	2021-08-05	Eisai Randd Man Co Ltd	Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso
TW202039554A (zh)	2018-12-19	2020-11-01	瑞士商諾華公司	抗ＴＮＦ－α抗體
JP7607564B2 (ja)	2018-12-21	2024-12-27	ノバルティスアーゲー	Ｐｍｅｌ１７に対する抗体及びその結合体
JP7486497B2 (ja)	2019-01-16	2024-05-17	ユニバーシティオブロチェスター	上皮または内皮バリア機能の改善
JP7393810B2 (ja)	2019-03-08	2023-12-07	アブティス・カンパニー・リミテッド	部位特異的抗体コンジュゲーション及びその具体例としての抗体－薬物コンジュゲート
US12291562B2 (en)	2019-04-01	2025-05-06	Rush University Medical Center	Reagents and assays using modified integrin domains
KR20220010527A (ko)	2019-05-20	2022-01-25	노파르티스 아게	친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트
CN114729045B (zh)	2019-09-26	2025-09-09	斯特库比公司	对糖基化的ctla-4特异性的抗体及其使用方法
US12595304B2 (en)	2019-10-09	2026-04-07	Stcube & Co., Inc.	Antibodies specific to glycosylated LAG3 and methods of use thereof
JP7657213B2 (ja)	2019-11-07	2025-04-04	エーザイ・アール・アンド・ディー・マネジメント株式会社	抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法
JP7449390B2 (ja)	2020-01-24	2024-03-13	ファイザー・インク	抗ｅ－セレクチン抗体、組成物および使用の方法
WO2021202473A2 (en)	2020-03-30	2021-10-07	Danisco Us Inc	Engineered antibodies
WO2021202463A1 (en)	2020-03-30	2021-10-07	Danisco Us Inc	Anti-rsv antibodies
US20230181756A1 (en)	2020-04-30	2023-06-15	Novartis Ag	Ccr7 antibody drug conjugates for treating cancer
CN116096758A (zh)	2020-05-01	2023-05-09	诺华股份有限公司	工程化免疫球蛋白
EP4143224A1 (en)	2020-05-01	2023-03-08	Novartis AG	Immunoglobulin variants
WO2021231798A1 (en)	2020-05-13	2021-11-18	Disc Medicine, Inc.	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
JP2023528826A (ja)	2020-05-29	2023-07-06	ウニヴェルジテート・ツー・ケルン	Ｓａｒｓ関連コロナウイルスに対する中和抗体
AR122546A1 (es)	2020-06-05	2022-09-21	Eisai R&D Man Co Ltd	Conjugados de anticuerpo anti bcma-fármaco y métodos de uso
JP2023532888A (ja)	2020-06-27	2023-08-01	クレセンタバイオサイエンシズ	細胞代謝を調節する化合物の組成及び使用方法
US11746154B2 (en)	2020-10-09	2023-09-05	Pfizer Inc.	CD1a antibodies and uses thereof
GB202017058D0 (en)	2020-10-27	2020-12-09	Kymab Ltd	Antibodies and uses thereof
US20240025993A1 (en)	2020-11-06	2024-01-25	Novartis Ag	Cd19 binding molecules and uses thereof
US20250215081A1 (en)	2020-11-06	2025-07-03	Novartis Ag	Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
JP2023547499A (ja)	2020-11-06	2023-11-10	ノバルティスアーゲー	抗体Ｆｃ変異体
CA3200858A1 (en)	2020-11-24	2022-06-02	Novartis Ag	Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
EP4259200A1 (en)	2020-12-11	2023-10-18	Boehringer Ingelheim International GmbH	Formulation for multi-purpose application
UY39610A (es)	2021-01-20	2022-08-31	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
GB202101125D0 (en)	2021-01-27	2021-03-10	Kymab Ltd	Antibodies and uses thereof
CA3235132A1 (en)	2021-04-16	2022-10-20	Novartis Ag	Antibody drug conjugates and methods for making thereof
EP4423123A1 (en)	2021-10-28	2024-09-04	Novartis AG	Engineered fc variants
GB202117111D0 (en)	2021-11-26	2022-01-12	Kymab Ltd	Antibodies for use as therapeutics against bacterial infections
EP4190810A1 (en)	2021-12-01	2023-06-07	Universität zu Köln	Neutralizing antibodies against sars-related coronavirus
EP4441090A1 (en)	2021-12-01	2024-10-09	Universität zu Köln	Neutralizing antibodies against sars-related coronavirus
US12138243B2 (en)	2021-12-31	2024-11-12	Crescenta Biosciences	Antiviral use of FABP4 modulating compounds
US20230357381A1 (en)	2022-04-26	2023-11-09	Novartis Ag	Multispecific antibodies targeting il-13 and il-18
WO2023245144A1 (en)	2022-06-16	2023-12-21	Vertos Medical, Inc.	Integrated instrument assembly
CA3262035A1 (en)	2022-07-15	2024-01-18	Janssen Biotech, Inc.	BIOLOGICALLY ENGINEERED IMPROVED MATERIAL AND PAIRING METHODS FOR VARIABLE ANTIGEN-BINDING REGIONS
EP4565330A1 (en)	2022-08-05	2025-06-11	Janssen Biotech, Inc.	Transferrin receptor binding proteins for treating brain tumors
CN120051495A (zh)	2022-08-05	2025-05-27	詹森生物科技公司	用于治疗脑肿瘤的cd98结合构建体
KR20250134734A (ko)	2022-12-16	2025-09-11	페온 테라퓨틱스 리미티드	Cub 도메인-함유 단백질 1(cdcp1)에 대한 항체 및 이의 용도
WO2024160721A1 (en)	2023-01-30	2024-08-08	Kymab Limited	Antibodies
EP4669667A2 (en)	2023-02-24	2025-12-31	Universität zu Köln	SARS-CoV-2 Neutralizing Antibodies
EP4484445A1 (en)	2023-06-26	2025-01-01	Universität zu Köln	Hcmv neutralizing antibodies
AU2024307442A1 (en)	2023-06-28	2026-02-19	Universität Zu Köln	Neutralizing human monoclonal antibodies against p. aeruginosa
WO2025262564A1 (en)	2024-06-17	2025-12-26	Pfizer Inc.	Use of anti-cxcr5 antibodies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1983001198A1 (en) *	1981-10-08	1983-04-14	Kurt Frimann Berg	Method and composition for treating a patient suffering from interferon-susceptible disorder
JPS62500589A (ja) *	1984-10-23	1987-03-12	ナステツク　フア−マス−テイカル　カンパニ−、インコ−ポレイテツド	抗吐き気および抗嘔吐薬剤の新規な投与組成物
JPS63152324A (ja) *	1986-11-05	1988-06-24	エチコン・インコーポレーテッド	表皮生長因子含有安定化組成物
JPH02112A (ja) *	1987-09-18	1990-01-05	Ethicon Inc	生長因子を含有するゲル配合物
JPH03502574A (ja) *	1987-12-03	1991-06-13	ザ　リポソーム　カンパニー，インコーポレイテッド	メチルセルロース製薬学的組成物
WO1993008845A1 (en) *	1991-11-08	1993-05-13	Massachusetts Institute Of Technology	Localized oligonucleotide therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US501714A (en) *		1893-07-18		Pocket pencil-holder
US4749700A (en) *	1984-10-23	1988-06-07	Nastech Pharmaceutical Co, Inc.	Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
ATE68686T1 (de) *	1985-10-31	1991-11-15	Kv Pharm Co	System zum freigeben von stoffen in der vagina.
US4810503A (en)	1987-03-31	1989-03-07	Basf Corporation	Polymers which form gels at low concentrations in water
US5258499A (en) *	1988-05-16	1993-11-02	Vestar, Inc.	Liposome targeting using receptor specific ligands
US5158761A (en) *	1989-04-05	1992-10-27	Toko Yakuhin Kogyo Kabushiki Kaisha	Spray gel base and spray gel preparation using thereof
US5246698A (en) *	1990-07-09	1993-09-21	Biomatrix, Inc.	Biocompatible viscoelastic gel slurries, their preparation and use
US5344644A (en) *	1991-08-01	1994-09-06	Takeda Chemical Industries, Ltd.	Water-soluble composition for sustained-release
RU2126262C1 (ru) *	1992-09-17	1999-02-20	Амген Боулдер Инк.	Фармацевтическая композиция
EP0599303A3 (en) *	1992-11-27	1998-07-29	Takeda Chemical Industries, Ltd.	Peptide conjugate
FR2723697B1 (fr) *	1994-08-17	1996-09-20	Rhone Poulenc Rorer Sa	Methode de traitement de la restenose par la therapie genique
US5552309A (en) *	1994-09-30	1996-09-03	Indiana University Foundation	Use of polyols for improving the introduction of genetic material into cells

1997
- 1997-03-03 DK DK97908818.4T patent/DK0885002T3/da active
- 1997-03-03 AU AU20631/97A patent/AU2063197A/en not_active Abandoned
- 1997-03-03 WO PCT/US1997/003276 patent/WO1997032572A2/en not_active Ceased
- 1997-03-03 EP EP97908818A patent/EP0885002B1/en not_active Expired - Lifetime
- 1997-03-03 US US08/810,275 patent/US5985320A/en not_active Expired - Lifetime
- 1997-03-03 ES ES97908818T patent/ES2395214T3/es not_active Expired - Lifetime
- 1997-03-03 PT PT97908818T patent/PT885002E/pt unknown
- 1997-03-03 AT AT97908818T patent/ATE508733T1/de active
- 1997-03-03 JP JP9531869A patent/JP2000506165A/ja active Pending

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1983001198A1 (en) *	1981-10-08	1983-04-14	Kurt Frimann Berg	Method and composition for treating a patient suffering from interferon-susceptible disorder
JPS62500589A (ja) *	1984-10-23	1987-03-12	ナステツク　フア−マス−テイカル　カンパニ−、インコ−ポレイテツド	抗吐き気および抗嘔吐薬剤の新規な投与組成物
JPS63152324A (ja) *	1986-11-05	1988-06-24	エチコン・インコーポレーテッド	表皮生長因子含有安定化組成物
JPH02112A (ja) *	1987-09-18	1990-01-05	Ethicon Inc	生長因子を含有するゲル配合物
JPH03502574A (ja) *	1987-12-03	1991-06-13	ザ　リポソーム　カンパニー，インコーポレイテッド	メチルセルロース製薬学的組成物
WO1993008845A1 (en) *	1991-11-08	1993-05-13	Massachusetts Institute Of Technology	Localized oligonucleotide therapy

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003534366A (ja) *	2000-05-25	2003-11-18	アルカームズコントロールドセラピューティクスインコーポレイテッド	改善された注射性を有する注射可能な懸濁物の調製
US7799345B2 (en)	2000-05-25	2010-09-21	Alkermes Controlled Therapeutics, Inc.	Preparation of injectable suspensions having improved injectability
JPWO2004078213A1 (ja) *	2003-03-06	2006-06-08	千佳子錦織	対象物質導入用組成物及び対象物質導入方法
JP2007525463A (ja) *	2003-05-12	2007-09-06	ベクトン・ディキンソン・アンド・カンパニー	インフルエンザワクチンの真皮送達を向上する分子
JP2007529558A (ja) *	2004-03-19	2007-10-25	レット・ゼア・ビー・ホープ、メディカル、リサーチ、インスティテュート	Ｃｔｌ／ｃｔｌｄの細胞炭水化物認識ドメインへターゲティングするための炭水化物誘導体化リポソーム、および治療的に活性な化合物の細胞内送達

Also Published As

Publication number	Publication date
AU2063197A (en)	1997-09-22
EP0885002B1 (en)	2011-05-11
DK0885002T3 (da)	2011-08-22
ATE508733T1 (de)	2011-05-15
EP0885002A2 (en)	1998-12-23
PT885002E (pt)	2011-07-14
ES2395214T3 (es)	2013-02-11
WO1997032572A2 (en)	1997-09-12
US5985320A (en)	1999-11-16
WO1997032572A3 (en)	1997-11-27

Legal Events

Date	Code	Title	Description
2004-03-18	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040226
2004-04-15	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040323
2008-01-15	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080115
2008-05-15	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080414
2008-06-02	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080602
2008-06-05	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080513
2008-06-23	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080623
2008-07-10	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080616
2008-07-28	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080728
2008-08-07	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080715
2009-11-10	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091110

Publication	Publication Date	Title
JP2000506165A (ja)	2000-05-23	細胞インターナリゼーションを増強するための物質および方法
WO1997032572A9 (en)	1997-12-31	Materials and methods for enhancing cellular internalization
USRE42072E1 (en)	2011-01-25	Compositions and methods for enhancing receptor-mediated cellular internalization
Peters et al.	2021	Advanced biomedical hydrogels: molecular architecture and its impact on medical applications
Pirmardvand Chegini et al.	2018	Recent approaches for targeted drug delivery in rheumatoid arthritis diagnosis and treatment
Dass	2002	Vehicles for oligonucleotide delivery to tumours
Kikuchi et al.	2002	Pulsatile drug release control using hydrogels
NZ220323A (en)	1991-04-26	3-dimensional network of microspheres containing biologically active macromolecular agents
Anal	2007	Stimuli-induced pulsatile or triggered release delivery systems for bioactive compounds
JP2000514086A (ja)	2000-10-24	内皮への標的のための遺伝子治療送達系
Nishimura et al.	2017	Self-assembled polypeptide nanogels with enzymatically transformable surface as a small interfering RNA delivery platform
EP1054694A2 (en)	2000-11-29	Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
CN113646003A (zh)	2021-11-12	多配体官能化的聚合物泡囊
EP3616702B1 (en)	2022-12-14	Prophylactic or therapeutic agent for inflammatory bowel disease
Kohane et al.	2003	pH-triggered release of macromolecules from spray-dried polymethacrylate microparticles
EP1507874A2 (en)	2005-02-23	Compositions and processes for inhibiting gene expression using polynucleotides
Dass et al.	2003	Modified microplex vector enhances transfection of cells in culture while maintaining tumour-selective gene delivery in-vivo
Nishikawa et al.	2008	Pharmacokinetic considerations regarding non‐viral cancer gene therapy
JP2011103790A (ja)	2011-06-02	金属イオンを含む高分子ナノ複合体
US11389545B2 (en)	2022-07-19	Bioactive nanoparticles and methods for making same
Oujagir et al.	2025	Therapeutic efficacy of in-vivo IL-12 plasmid delivery using microbubble-assisted ultrasound in a B16F10 mouse melanoma model: A proof of concept
JP2024524200A (ja)	2024-07-05	能動的マイクロボットを用いた局所送達用の医薬品有効成分（ａｐｉ）含有製剤
CN118490619A (zh)	2024-08-16	一种免疫激活微针及其制备方法和应用
CN101259289A (zh)	2008-09-10	用于rna干扰的治疗用途的方法及组合物
WO2000035512A2 (en)	2000-06-22	Device and method for delivery of a therapeutic agent to a target tissue in vivo